Despite broad approvals based on intent-to-treat populations, adjuvant immune checkpoint inhibitors have shown hazard ratios above 1.0 for both disease-free and overall survival in upper tract subsets across trials like CheckMate 274 (HR 1.23) and IMvigor010. Consequently, oncologists hesitate to extrapolate bladder cancer trial outcomes to upper tract disease, as dedicated evidence demonstrating a therapeutic benefit in this anatomical subgroup remains absent.
Rare malignancies like upper tract urothelial carcinoma struggle to enroll sufficiently powered randomized trials, taking up to eight years to report overall survival. Instead of waiting for traditional phase III registrational designs, experts advocate conducting smaller, 100-patient non-traditional studies using ctDNA clearance as an early surrogate endpoint. This strategy enables rapid evaluation of novel antibody-drug conjugate and immunotherapy combinations to inform clinical care far sooner.
Although the POUT trial established adjuvant platinum chemotherapy for upper tract urothelial cancer, the carboplatin subgroup yielded a weaker overall survival hazard ratio of 0.86 with drifting disease-free survival. Because carboplatin historically failed in neoadjuvant bladder cancer, guidelines like ESMO restrict recommendations to cisplatin, leaving cisplatin-ineligible patients facing substantial toxicity—44% grade 3 or 4 adverse events in POUT—without convincing survival data.
Circulating tumor DNA (ctDNA) provides more actionable risk stratification than pathologic stage in resected upper tract disease. Patients who test ctDNA negative exhibit a low 20% to 30% risk of recurrence, making active surveillance reasonable to avoid toxic, marginally effective adjuvant therapies. Conversely, ctDNA positivity behaves like occult metastatic disease with recurrence rates approaching 95%, prompting clinicians to bypass adjuvant platinum for full-dose enfortumab vedotin plus pembrolizumab.
Even though CheckMate 274 showed improved disease-free survival in PD-L1-positive patients overall, oncologists caution against relying on PD-L1 to prescribe adjuvant nivolumab for upper tract tumors. Across urothelial cancer trials—including frontline metastatic settings—the PD-L1 biomarker has repeatedly failed to predict outcomes reliably. Furthermore, regulatory labels do not mandate PD-L1 testing, making it an unreliable surrogate for overcoming negative upper tract checkpoint inhibitor performance.
